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Purpose: The molecular mechanisms that are responsible for the initiation and 
progression of breast cancers are largely unknown. This study was to analyze the 
cyclin B1, cdc2, p53 and p16 tumor suppressor genes in human breast cancer.     
Materials and Methods: To investigate the role of cyclin B1, cdc2, p53 and p16 
in the pathogenesis and progression of breast carcinomas, 98 cases of breast can-
cers were examined by immunohistochemical method. The correlations of cyclin 
B1, cdc2, p53 and p16 expression with various clinico-pathologic findings were 
analysed. Results: In the normal breast tissues, cyclin B1, cdc2 and p16 were 
weakly expressed, while p53 was not expressed. On the other hand, cyclin B1, 
cdc2, p53 and p16 were overexpressed in breast cancer, showing correlation be-
tween the expression of cyclin B1 and cdc2 and breast cancers (p=0.00). The over-
expressions of cdc2 and p16 were correlated with an infiltrative tumor border pat-
tern and this was statistically significant (p<0.05). In addition, the overexpression 
of cdc2 was correlated with histologic high grade carcinomas (p=0.00). Conclu-
sion: Cyclin B1 and cdc2 appeared to be involved in the genesis or progression of 
breast cancers. In addition, the overexpressions of p16 and p53 may play impor-
tant roles in more aggressive tumor and the overexpression of cdc2 is associated 
with progression of tumor to a higher grade of breast carcinomas. The deranged 
overexpressions of cyclin B1, cdc2, p16 and p53 may play an important role in hu-
man breast carcinogenesis. 
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INTRODUCTION
Breast cancer is one of the most common types of cancer among women and it is 
the major cause of cancer death in the Korean population.1 Although the pathologi-
cal staging classification of the disease is known to be the most important parame-
ter that is related with the patients’ clinical outcomes, clinico-pathological studies 
have shown that breast cancers are quite heterogenous, so that they reveal unpre-
dictable biological behaviors. Therefore, it is necessary to find novel markers that Seoung Wan Chae, et al.
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unless a cyclin is present. p16 regulation is an essential step 
in the pathway that links mitogenic signals to cell cycle 
progression.17      
The p53 gene is located on the short arm of chromosome 
17, and alterations in the p53 gene are the most common 
genetic lesions observed in human neoplasm.18 The func-
tional derangement of the tumor suppressor gene p53 has 
been implicated as the main mechanism leading to the loss 
of cell-cycle control in human malignancies.19 The loss of 
wild-type p53 has been reported to be associated with hu-
man breast carcinomas.12
In this study, we examined the expressions of cyclin B1, 
cdc2, p16 and p53 in 98 cases of breast cancers by an im-
munohistochemical method, and analyzed the correlations 
of the expressions of cyclin B1, cdc2, p16 and p53 with vari-
ous clinico-pathologic findings. 
MATERIALS AND METHODS
Study population 
Ninety-eight cases of breast cancer that were histologically 
diagnosed from 2000 to 2008 at Kangbuk Samsung Hospital 
were included in this study. Also eighty-two cases of normal 
breast tissue which were taken from specimen after plastic 
surgery were included. The follow-up data of the cases were 
retrospectively retrieved from the clinical records of the hos-
pital and the families of the patients. The classification, diag-
noses and staging of breast cancers were done based on the 
AJCC Cancer staging manual of the American Joint Com-
mittee on Cancer.20 The histologic grade was determined by 
the Nottingham combined histologic grade (tubule forma-
tion, nuclear pleomorphism and mitotic count), assigning a 
value of 1 (favorable) to 3 (unfavorable) for each feature, and 
adding the scores together for all three categories.21 
The study was strictly performed according to the Decla-
ration of Helsinki and approved by the local Ethics Com-
mittee of the Kangbuk Samsung Hospital.
Immunohistochemical staining 
All of the tissues obtained from patients were routinely 
fixed in 10% buffered formalin and embedded in paraffin 
blocks. We produced the tissue microarray (TMA) blocks 
containing 2-mm diameter cores of the breast cancer tissues 
from the enrolled cases. One core was obtained from cen-
tral portion of the mass on each case. The TMA blocks were 
sectioned at a 4 µm-thickness and were processed for im-
are related to the biological behavior of breast tumors. Such 
trials have been done by using immunohistochemical or 
molecular biologic techniques.2-12
Because of the recent advances in understanding how the 
cell cycle is controlled and how it becomes deranged in 
cancer, various cell cycle regulators are now candidates as 
molecular markers. It has been shown that cell growth is 
tightly controlled by interactions of cyclins, cyclin depen-
dent kinases (CDKs) and CDK inhibitors (CDKIs). Cyclins 
are proteins that govern progression through key check-
points in the cell cycle and they act directly to regulate the 
activity of the central cell cycle kinase cdc2 and other relat-
ed kinases.3-6 The dysregulated overexpression of cyclins 
appears to be involved in uncontrollable cell proliferation 
and early tumor development. Cyclin B1 regulates the G2-M 
transition of the cell cycle.13-15
Cdc2 is a protein that is expressed by the cdc2 gene. Cdc2 
functions in conjunction with cyclin B1 to control mitosis.2 
Regulation of cdc2 activity is a complex process that in-
volves cyclin binding, subunit phosphorylations, CDKI 
binding and cyclin degradation. The cyclin/CDK complex-
es are known to function in regulating the cell-cycle. The 
cyclin/CDK complexes stimulate cell cycle progression, 
and the CDKIs induce cell cycle arrest by counteracting 
CDKs.3,14,15 The cyclin B1/cdc2 complex, which functions 
as a G2-M checkpoint, is essential for DNA mitosis. The 
cyclin B1/cdc2 complex functions in conjunction with CD-
KIs to control mitosis.2,7,15,16
The CDKIs identified in mammary cells are subdivided 
into two major classes. One family includes p15INK4B/MTS2, 
p16INK4A/MTS1 and p18. p27Kip1, p21WAF1/Cip1 and p57Kip2 form 
the other family of CDKIs, which are structurally unrelated 
to the INK4 family (p15INK4B/MTS2, p16INK4A/MTS1 and 
p18).10,11,17 The tumor suppressor protein p16 is a cyclin-de-
pendent kinase inhibitor that negatively regulates cell pro-
liferation by inhibiting the kinase activity of CDK4 and 
CDK6, and the tumor suppressor protein p16 subsequently 
promotes phosphorylation and inactivation of the tumor 
suppressor protein pRb. p16 is also a negative regulator of 
the mammarian cell cycle.10,11 Normal proliferating cells do 
not express significant levels of p16 prior to extensive 
rounds of cell division, which may suggest a late-stage, an-
ti-proliferative role for p16 as in replicative cell senescence. 
p16 has broad specificity in vitro: it inhibits the kinase ac-
tivity of the G1 cyclin complexes (Cyclin A-CDK2, Cyclin 
D-CDK4, and Cyclin E-CDK2) and, to lesser extent, the 
mitotic cdc2 and p16 do not associate with kinase subunits A Survey of 98 Cases
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RESULTS
Clinical data 
All 98 cases were women and their age ranged from 28 to 
79 years, with a mean age of 50.1±10.2 years. The median 
follow-up period was 80 months (range: 13 months to 118 
months). The survival of patients was grouped as no evi-
dence of disease (NED)(n=80), dead of disease (DOD)
(n=9) and alive with disease (AWD)(n=9). There were 29 
cases of stage I, 35 cases of stage IIa, 14 cases of stage IIb, 
11 cases of stage IIIa, 1 case of stage IIIb and 8 cases of stage 
IIIc. The histologic subtypes included invasive ductal carci-
noma (IDC)(n=91) and others (n=7). 
Expressions of cyclin B1, cdc2, p16 and p53 in breast 
cancers 
The clinico-pathologic parameters included tumor type, tu-
mor size, tumor grade, tumor margin, lymphatic invasion, 
vascular invasion, perineural invasion, nodal involvement, 
nodal pathologic classification, extensive intraductal com-
ponent, tumor necrosis, tumor recurrence, survival state, age, 
estrogen receptor, progesterone receptor, her-2 and stage. 
The clinical data of the patients and the relationships be-
tween the clinico-pathologic parameters and the cyclin B1, 
cdc2, p16 and p53 expressions in 98 human breast carcino-
mas are summarized in Table 1. Two pathologists indepen-
dently examined the cases and, if there was disagreement, 
we had a mutual agreement with an another pathologist. 
However, there was trivial interobserver variations on inter-
pretation. Cyclin B1, cdc2, p16 and p53 were diffusely ex-
pressed in 56 cases (57.1%), 53 cases (54.1%), 68 cases 
(69.4%) and 57 cases (58.2%), respectively, out of 98 cases 
with breast cancers. The mean labeling indices of cyclin B1 
and cdc2 were 31.8% and 38.3%, respectively. The immu-
nostaining of cyclin B1 was predominantly detected in the 
cytoplasm, and cdc2 staining was mainly detected in the 
cytoplasm and to lesser extent in the nuclei. In the normal 
breast tissue, cyclin B1 and cdc2 were weakly expressed in 
the cytoplasm (Fig. 1A-D). Other cells, such as lympho-
cytes, monocytes and macrophages, did not show cyclin B1 
and cdc2 immunostains. The mean labeling indices of cy-
clin B1 and cdc2 in the glandular epithelial cells of the nor-
mal breast tissues were 5% and 10%, respectively, and these 
findings were statistically significant (p<0.05). The immu-
nostaining of p16 was detected in the nuclei and cytoplasm 
(Fig. 1E), and p53 was predominantly detected in the nuclei 
munohistochemistry. The slides were dehydrated, deparaf-
finated in xylene and then rehydrated in a graded series of al-
cohol solutions. The antibodies used were cyclin B1 (mouse 
monoclonal IgG1, Santa Cruz Biotechnology, Santa Cruz, 
CA, USA, 1 : 100), cdc2 (mouse monoclonal IgG2a, Santa 
Cruz Biotechnology, Santa Cruz, CA, USA 1 : 100), p16 
(mouse anti Human E6H4, CINTEC, Heidelberg, Deutsch, 
1 : 100) and p53 (monoclonal Rabbit Anti-Human 318-6-
11, Dako, Glostrup, Denmark, 1 : 100). The immunostain-
ing was performed with a compact polymer method (in a 
Bond Intense detection kit, Leica Biosystems, Newcastle, 
UK). Diaminobenzidine (DAB) was the chromogen and 
Meyer’s hematoxylin was used for counterstaining. After 
three representative areas of the breast carcinomas were pho-
tographed using a digital camera under ×200 magnification, 
the numbers of all the cells and the positively stained cells 
were counted to assess the expressions of cyclin B1, cdc2, 
p16 and p53. The cytoplasmic and/or nuclear immunostain-
ings were considered positive for cyclin B1, cdc2 and p16. 
Nuclear staining was considered positive on the immunos-
taining for p53. Positive staining in more than 10% of the 
tumor cells was considered positive. The cut off values in 
our study were defined previously,5,8,9 and we thought that 
10% was optimal cut off value to evaluate statistical analy-
ses. For the case of normal breast tissue, three representa-
tive areas were photographed under ×200 magnification in 
the mammary ductal epithelial areas. Clinical positive con-
trol cases for all the markers were included in every batch 
of staining. As a negative control, rabbit and mouse IgG 
isotypes were used instead of the primary antibodies. 
The scores were entered into a Microsoft Excel spread-
sheet. The scoring results were separated into two catego-
ries, either negative or positive. The uninterpretable results 
were eliminated from further consideration. 
  
Statistical analyses 
The relationships between the expressions of cyclin B1, 
cdc2, p16 and p53 and the various clinicopathological find-
ings were evaluated using the Fisher exact test and the Pear-
son Chi-square test. The Kaplan-Meier survival curves were 
generated to access whether any level of cyclin B1, cdc2, 
p16 and p53 had any effect on the overall survival of patients 
with breast cancer and the resulting curves were compared 
using the log-rank test. p values less than 0.05 were consid-
ered to be statistically significant. The statistical analyses 
were performed with PASW Statistics 17.0 (SPSS Inc., Chi-
cago, IL, USA).Seoung Wan Chae, et al.
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Table 1. Association between the Clinico-Pathologic Parameters and the Cyclin B1, cdc2, p16 and p53 Expressions in 98 Hu-
man Breast Carcinomas
Cyclin B1 p value  cdc2 p value p16 p value p53 p value
No. of expressions/total cases 56/98 (57.1%) 53/98 (54.1%) 68/98 (69.4%) 57/98 (58.2%)
Tumor type  0.48 0.64 0.54 0.49
IDC (n=91) 51 50 63 54
Others (n=7)   5   3   5   3
Tumor size 0.34 0.73 0.57  0.12
    ≥2 cm (n=68) 41 36 46 36
    <2 cm (n=30) 15 17 22 21
Tumor grade 0.59 0.00 * 0.57  0.11
    1 (n=23) 11   5 18    9
    2 (n=38) 23 23 25  24
    3 (n=37) 22 25 25  24
Tumor margin 0.83 0.04 *     0.04 * 0.70
    Infiltrative (n=76) 43 37 49   45
    Pushing (n=22) 13 16 19 12
Lymphatic invasion 0.91 0.39  0.97 0.92
    Absent (n=52) 30 26 36  30
    Present (n=46) 26 27 32  27
Vascular invasion 1.00 0.07  0.82 0.92
    Absent (n=77) 44 38 53  45
    Present (n=21) 12 15 15  12
Perineural invasion 0.74 0.11  0.50 0.25
    Absent (n=73) 41 36 52  40
    Present (n=25) 15 17 16  17
Nodal involvement 0.86 0.12  0.84 0.95
    Absent (n=57) 33 27 40  33
    Present (n=41) 23 26 28  24
Nodal pathologic classification 0.61 0.36  0.72 0.63
    pN0 (n=57) 33 27 40 33
    pN1a (n=16)   9   9 12   8
    pN1b (n=4)   4   3   2   3
    pN1c (n=1)   1   0   1   1
    pN2a (n=7)   3   6   6   3
    pN2b (n=5)   2   2   3   4
    pN3a (n=2)   1   2   1   2
    pN3b (n=5)   2   3   2   2
    pN3c (n=1)   1   1   1   1
Extensive intraductal component 0.52 0.43  0.76 0.21
    Absent (n=50) 27 29 34 26
    Present (n=48) 29 24 34 31
Tumor necrosis 0.64 0.62  0.84 0.87
    Absent (n=54) 32 28 37 31
    Present (n=44) 24 25 31 26
Tumor recurrence 0.77 0.39  0.80 0.49
    Absent (n=94) 54 50 65  54
    Present (n=4)   2   3   3    3
Survival state 0.42 0.43  0.85 0.38
    Alive (n=89) 52 47 62  53
    Death (n=9)   4   6   6    4
Age 0.29 0.12 0.12   0.37A Survey of 98 Cases
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statistically significant (p<0.05). 
Correlations between the cyclin B1, cdc2, p16 and p53 
expressions in breast cancer 
The cyclin B1 expression showed a tendency to increase 
according to that of cdc2, and it was statistically significant 
(p=0.00). However, the correlations between the expres-
sions of cyclin B1 and p16 and between the expressions of 
cyclin B1 and p53 were not statistically significant (Table 
(Fig. 1F). In the normal breast tissue, p16 was weakly ex-
pressed in the nuclei and cytoplasm, but p53 was not ex-
pressed. The cdc2 and p16 expressions were 69.8% and 
72.1% in the cases with an infiltrative tumor border, where-
as 30.2% and 27.9% in the cases with a pushing tumor bor-
der, respectively, and these findings were statistically signif-
icant (p<0.05). In addition, cdc2 expression was seen in 
21.7% of the grade 1 cases, in 60.5% of the grade 2 cases 
and in 67.6% of the grade 3 cases, and these findings were 
Table 1. Continued
Cyclin B1 p value  cdc2 p value p16 p value p53 p value
    ≤45 (n=41) 26 26   32 26
    >45 (n=57) 30 27 36 31
ER 0.74 0.82 0.86   0.10
    Positive (n=73) 41 39 51  39
    Negative (n=25) 15 14 17  18
PR 0.80  0.46 0.95 0.70
    Positive (n=69) 40 39 48 41
    Negative (n=29) 16 14 20 16
Her-2 0.23 0.21 0.29 0.30
    Positive (n=37) 24 23 28 24
    Negative (n=61) 32 30 40 33
Stage 0.40 0.48 0.81   0.47
    I (n=29) 15 13 22 20
    IIA (n=35) 24 17 23  17
    IIB (n=14)   8   9 10   8
    IIIA (n=11)   4   7   8   6
    IIIB (n=1)   1   1   1   1
    IIIC (n=8)   4   6   4   5
IDC, invasive ductal carcinoma; ER, estrogen receptor; PR, progesterone receptor.
*p<0.05. 
Fig. 1. Immunostainings for cyclin B1 and cdc2 in normal breast tissue and invasive ductal carcinoma. Cyclin B1 is weakly and multifocally highlighted in the 
cytoplasm of normal mammary ductal cells (A), whereas carcinoma cells diffusely express cyclin B1 in the cytoplasm (B). cdc2 is weakly and multifocally high-
lighted in the cytoplasm of normal mammary ductal cells (C), whereas it was detected mainly in the cytoplasm and to lesser extent in the nuclei (D) of carcino-
ma cells. p16 (E) is diffusely detected in the nuclei and cytoplasm (E) and p53 (F) is strongly expressed in the nuclei of invasive ductal carcinoma cells.
A B C
D E FSeoung Wan Chae, et al.
Yonsei Med J   http://www.eymj.org   Volume 52   Number 3   May 2011 450
ported in the literature5 that cyclin B1 is overexpressed at a 
relatively high frequency (42%) when detected by an im-
munohistochemical method, and it has been found to corre-
late with various clinico-pathologic parameters including 
high tumor grade and distant metastasis. In our study, cy-
clin B1 overexpression was detected in breast cancers, sim-
ilar to earlier studies,3,5,6 however, it was not correlated with 
any clinico-pathologic parameters, unlike the results of the 
previous studies.3,5 Therefore, further follow up cohort study 
is needed .
In our present study, cdc2 was overexpressed in 54.1% of 
the cases and this was associated with a higher histologic 
grade and infiltrative growth pattern. Some studies found that 
a cdc2 overexpression occurs at a high frequency (66%) and 
it is associated with a higher histologic grade and a p53 ex-
pression.8 Our results are in partial agreement with those of 
Kourea and co-workers,8 who noted a positive association of 
the tumor grade with a cdc2 overexpression. These findings 
probably reflect a measure of proliferative cellular activity.22
In this immunohistochemical study, the mean labeling in-
2). The correlations between the expressions of cdc2 and 
p16 and between the expressions of cdc2 and p53 were not 
statistically significant (Table 3). Furthermore, the correla-
tion between the expressions of p53 and p16 was not statis-
tically significant (Table 4).
 
Survival analyses
The survival rate was calculated for the 98 patients, and the 
mean observation duration was 81.7±4.5 months. There 
was no significant difference in survival according to the 
expressions of cyclin B1, cdc2, p16 and p53, regardless of 
the cut-off value for the Kaplan-Meier survival curves (Fig. 
2). There was no influence on the overall survival accord-
ing to the expressions of cyclin B1, cdc2, p16 and p53.
DISCUSSION
In the present study, cyclin B1 was found to be diffusely 
expressed in 57.1% of the cases. It has generally been re-
Table 2. The Correlations between the Cyclin B1, cdc2, p16 and p53 Expressions
Cyclin B1 expression
p value*
Negative Positive
cdc2 expression 0.00 
    Negative (n=45) 28/45 (62.2%) 17/45 (37.8%)
    Positive (n=53) 14/53 (26.4%) 39/53 (73.6%)
p16 expression 0.07
    Negative (n=30) 17/30 (56.7%) 13/30 (43.3%)
    Positive (n=68) 25/68 (36.8%) 43/68 (63.2%)
p53 expression 0.16
    Negative (n=41) 21/41 (51.2%) 20/41 (48.8%)
    Positive (n=57) 21/57 (36.8%) 36/57 (63.2%)
*Pearson Chi-square test 
Table 3. The Correlation between the cdc2, p16 and p53 Expressions
cdc2 expression
p value
Negative Positive
p16 expression 0.16
    Negative (n=30) 17/30 (56.7%) 13/30 (43.3%)
    Positive (n=68) 28/68 (41.2%) 40/68 (58.8%)
p53 expression 0.09
    Negative (n=41) 23/41 (56.1%) 18/41 (43.9%)
    Positive (n=57) 22/57 (38.6%) 35/57 (61.4%)
Table 4. The Correlation between the p16 and p53 Expressions
p16 expression
p value
Negative Positive
p53 expression 0.26
    Negative (n=41) 10/41 (24.4%) 31/41(75.6%)
    Positive (n=57) 20/57 (35.1%)  37/57 (64.9%)A Survey of 98 Cases
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During interphase, cyclin B1 is initially localized in the cy-
toplasm due to the function of the cytoplasmic retention se-
quence. Then, most of the cyclin B1-cdc2 complex are rap-
idly translocated from the cytoplasm to the nucleus in late 
prophase. Therefore, the cyclin B1 and cdc2 overexpres-
sions may be caused by unlimited protein synthesis, impaired 
proteolytic degradation and due to some other reasons.14,16 
The mechanism of how cyclin B1 and cdc2 participate in tu-
mor progression is not clear. p53 inactivates cdc2 kinase, 
which controls the G2 checkpoint in the cell cycle. This cdc2 
kinase inactivation results from the repression of cyclin B1 
and cdc2 transcription. The enforced expression of both cy-
clin B1 and cdc2 leads to overriding p53-mediated G2-M 
arrest. The constitutive activation of cyclin B1-associated 
cdc2 kinase overrides p53-mediated cell cycle arrest, so 
that the cell cycle can continue without the G2 checkpoint 
in cases where cyclin B1 is overexpressed. Nevertheless, it 
remains to be determined how the overexpressions of cy-
clin B1 and cdc2 are involved in oncogenesis and tumor 
progression.
dices of cyclin B1 and cdc2 in breast carcinomas were 31.8% 
and 38.3%, respectively, and those of cyclin B1 and cdc2 in 
the mammary ductal cells of normal breast tissues were 5% 
and 10%, respectively, showing much lower than those of 
the breast carcinomas. There was quite different staining 
patterns between breast carcinomas and normal breast tis-
sues: In the normal breast tissue, there was a multifocal 
staining pattern of cyclin B1 and cdc2. In contrast, howev-
er, cyclin B1 and cdc2 were diffusely expressed in the breast 
carcinomas. The reason why the labeling index of cdc2 is 
higher than that of cyclin B1 in both normal breast tissue 
and cancer breast tissues is not definite. But the fact that 
cdc2 is present during all phases of cell cycle, except G0 
phase, however cyclin B1 is expressed in the later phases of 
cell cycle and re-synthesized on the beginning of S phase 
may be the reason of those results.23 In our study, the corre-
lation between the overexpressions of cyclin B1 and cdc2 
was noted, and it was statistically significant. These results 
suggest that cyclin B1 and cdc2 cooperate closely to play a 
role in the progression or genesis of breast carcinomas. 
Fig. 2. Kaplan-Meier survival curve stratified according to the extent of cyclin B1 (A), cdc2 (B), p16 (C) and p53 (D). When the expression of cyclin B1 was 
stratified as 10% or over (n=56) and below 10% (n=42), the survival curve of cyclin B1 shows no significance (A). When the expression of cdc2 was stratified 
as 10% or over (n=53) and below 10% (n=45), the survival curve of cdc2 shows no significance (B). When the expression of p16 was stratified as 10% or over 
(n=68) and below 10% (n=30), the survival curve of p16 shows no significance (C). When the expression of p53 was stratified as 10% or more (n=57) and be-
low 10% (n=41), the survival curve of p53 shows no significance (D). 
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important roles in more aggressive tumor, and that the over-
expression of cdc2 is associated with progression of tumor 
to a higher grade of breast carcinomas. Significant difference 
in the cyclin B1 and cdc2 values between normal mammary 
ductal epithelial cells and breast carcinomas indicates a 
consequential role for the overexpressions of cyclin B1 and 
cdc2 in the malignant transformation of breast epithelial 
cells. Future studies to examine resected human breast tu-
mor samples are required to better delineate effectors that 
mediate the malignant phenotype. This is essential in order 
to better understand the mechanisms that regulate breast 
carcinogenesis. 
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